Lipid colloidal systems: a strategy to deliver natural bioactive compounds by Lopes, Carla Martins
Citation: Lopes CM. Lipid Colloidal Systems: A Strategy to Deliver Natural Bioactive Compounds. Austin 
Therapeutics. 2014;1(3): 2.
Austin Therapeutics - Volume 1 Issue 3 - 2014
Submit your Manuscript | www.austinpublishinggroup.com 
Lopes. © All rights are reserved
Austin Therapeutics
Open Access
(e.g. 3-nitroflavones series) [9], competitive and selective ligands for 
central benzodiazepine receptors and in vivo potent anxiolytic activity 
(e.g. 3-hydroxy-2’-methoxy-6-methylflavone) [6], anti-inflammatory 
(e.g. methoxylated chalcones) [4] and antimicrobial activities (e.g. 
7,3`-dihydroxy-4´methoxyflavone) [10]. In my point of view, the 
most hopeful therapeutic activity is their selective anti-proliferative 
effects. Some of them are reported as in vitro potent antiproliferative 
agents against a panel of different human and murine tumor cell 
lines [4,5,8]. For example, Cardenas et al. [5] verified that synthetic 
2`-nitroflavone significantly reduced the growth in 5 different 
tumor cell lines (i.e. cervix HeLa adenocarcinoma, oropharyngeal 
KB carcinoma, human cervical WISH carcinoma, breast MCF-7 
cancer, F3II and LM3, both mammary adenocarcinoma). None 
of the tested compounds affected the proliferation of non-tumor 
epithelial cells, suggesting a selective effect against cultured tumor 
cells. In another study, Bandgar et al. [7] demonstrated that the 
introduction of a nitro group in the 3,4,5-trimethoxy chalcones 
completely inhibited the growth of human cancer cell lines (i.e. renal 
ACHN carcinoma, pancreatic Panc1 carcinoma, non small cell lung 
Calu1 carcinoma, non cell lung H460 carcinoma and colon HCT116 
carcinoma) as compared to standard anticancer agents (flovopiridol 
and gemcitabine) and exhibited promising anti-inflammatory 
and antioxidant activities which seems to be beneficial for cancer 
treatment also. However, Liu and collaborators [8] reported that the 
use of nitro substituent to synthesize 6-isopropyl-3`-nitroflavone and 
6-isopropyl-4`-nitroflavone inactivated the flavones antiproliferative 
effect against HepG-2 cells (i.e. a human hepatocellular carcinoma cell 
line), proving the significance of the structure-activity relationship. 
Additionally, a specific compound, 3`-methoxy-4`-nitroflavone, may 
act as an aryl hydrocarbon receptor agonist or antagonist of tumor 
cells based on its concentration and on the promoter context of 
particular gene [11].
A significant hurdle in the translation of these potential 
natural therapeutic candidates into the clinical domain lies is their 
inadequate delivery to the intended site of action. So, it is deemed 
to develop appropriate carriers for efficacy delivering the bioactives 
to their target (i.e. cells/tissues or organs). It is well known that 
the cellular delivery of compounds is affected by both the lack of 
selectivity of a number of compounds and the high restriction of 
transport therapeutic agents across cellular membranes [12]. In the 
topic of advanced drug delivery, various strategies can be adopted to 
improve the transport into the target site but nanoscale carries have 
been stimulated the burgeoning interest in the subject. Concerning 
the entrance of nanoparticles to the tissues structures, there are 
some approaches reported in the literature [13]. Therefore, one 
important mechanism is the passive delivery and targeting where 
the nanocarriers reach end points by the natural mechanisms, 
namely through enhanced permeability and retention effect [14]. 
For example, some organs present natural affinity for nanoparticles 
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The lifecycle of a pharmaceutical product begins with the initial 
discovery of potential new therapeutic candidates. In this stage, many 
of these candidates are based on natural products due to their well 
documented beneficial effects on human health [1]. Once natural 
products often have complex structural features and, generally, 
their bioactivity is tightly correlated with their chemical structure, 
the continuous advances in chemical synthetic methodology have 
offered practical access to the so called nature-identical materials (i.e. 
natural substances produced synthetically in an identical molecular 
form) [2]. Therefore, natural products can be used as clinically useful 
therapeutic compounds, as starting materials to produce synthetic 
drugs, or as guide compounds from which a totally synthetic drug 
is developed, avoiding interactions between different compounds 
present in botanical preparations [2]. The exploitation of these 
synthetic derivatives in the development of new pharmaceutical 
products is a promising field, requiring interdisciplinary research 
groups like chemists, pharmaceutical technologists, biochemists, 
toxicologists, pharmacologists. 
One of the most promising examples of natural sources of 
therapeutic bioactive compounds is the flavonoids. I focused my 
short revision on this class of compounds. They are heterocyclic 
polyphenolic compounds which are broadly distributed in plants 
and dietary components (e.g. fruits, olive oil, vegetable, tea, red 
wine) and, therefore, are believed to be non-toxic [3]. A close 
relationship between the chemical structure of flavonoids and in 
vitro biologic activity are reported in the literature, suggesting that 
their basic structure can be chemically modified to increase or 
decrease their biologic potency activity [4-6]. Therefore, attending 
to their pharmacological input to health, diverse synthetic flavones 
derivatives (e.g. nitro, amino, methoxylate) have been developed by 
several groups of chemical researchers in the last decades [4-10]. These 
compounds have displayed important biological effects such as chemo 
protective action against colon aberrant crypt foci in the rat colon 
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uptake (e.g. liver and spleen) mainly due to the absorption by 
reticuloendothelial system and pathological situations that present an 
enhanced vascular permeability like some tumors and inflammation-
related diseases [15]. The active targeting through selective implies 
focused seeking out of the target, mostly through specific interaction 
of the surface targeting ligands on delivery system with receptors 
in the target site [16]. Among biomaterials-nanocarriers, those 
composed of lipids materials (e.g. liposomes and lipid nanoparticles) 
have unique properties, such as biocompatibility, biotolerability once 
they are composed by lipids similar to the physiological ones, which 
make them first-class excipients in formulations [17].
Liposomes have encountered some challenges, such as high in 
vivo instability, which results in fast drug release and short blood 
circulation half-life, and also limited physical stability during storage. 
Once many of synthetic bioactive of natural products are not water 
soluble, the use of lipid nanoparticles seems to be attractive approach 
to deliver them. Lipid nanoparticles are consider superior carriers 
which claimed to join the advantages of older and well-known other 
colloidal carriers (e.g. liposomes and polymeric nanoparticles) and 
to avoid some of their drawbacks, namely decrease the toxicity of 
cytotoxics and increase the expected bioactive`s in vivo half-life, 
mainly if nanoparticles are coated with hydrophilic polymer on their 
surface [18]. Lipid nanoparticles offer an economical and patient-
friendly device to deliver drugs in various routes of administration 
(e.g. parenteral, oral, pulmonary, and intranasal) [19]. The direct 
visualization (gamma scintigraphy imaging) of nanocarriers-
loaded bioactives in blood circulation and biodistribution following 
their administration to animals can play an essential role to screen 
the most promising activities and afterwards in clinical practices. 
Based on these considerations, further lipid nanoparticles could 
be functionalized with surface ligands to obtain defined biological 
response. In conclusion, the potential of biomaterials-nanocarriers as 
drug delivery systems is widespread nowadays, and so far it seems to 
be a smart idea.
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